March 12 (Reuters) - Mallinckrodt Pharmaceuticals MCKPF.PK and Endo NDOI.PK are exploring a potential merger that could be valued at about $7 billion, Bloomberg News reported on Wednesday, citing people with knowledge of the matter.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.